DIFLUCAN (fluconazole) by Pfizer is cytochrome p450 2c19 inhibitors [moa]. First approved in 1993.
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
DIFLUCAN (fluconazole) is an oral azole antifungal agent that works by inhibiting fungal cytochrome P450 2C19, disrupting ergosterol synthesis in fungal cell membranes. Approved in 1993, it is used to treat various fungal infections across multiple body systems. The drug has become a standard-of-care option for candidiasis and other fungal infections in both immunocompromised and immunocompetent patients.
As LOE approaches with minimal Part D spending, the brand team is likely contracting; career opportunities focus on generic transition management and niche positioning rather than growth expansion.
Cytochrome P450 2C19 Inhibitors
Azole Antifungal
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS
Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS
A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis
A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
Worked on DIFLUCAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on DIFLUCAN offers limited growth trajectory but provides valuable experience in mature-product management, healthcare economics, and institutional relationships. Career advancement on this product likely requires cross-functional skills or transition to higher-growth franchises within Pfizer's portfolio.